Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening: Results from a Population-based Study, 2003–2011

This publication has 25 references indexed in Scilit:

• Prostate-Cancer Mortality at 11 Years of Follow-up
  New England Journal of Medicine, 2012
• Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
  JNCI: Journal of the National Cancer Institute, 2012
• Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force
  Annals of Internal Medicine, 2011
• Prostate‐specific antigen testing rates remain low in UK general practice: a cross‐sectional study in six English cities
  BJU International, 2011
• EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease
  European Urology, 2011
• Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study
  BMJ, 2010
• A systematic review of the diagnostic accuracy of prostate specific antigen
  BMC Urology, 2009
• Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey
  Cancer, 2007
• Rates of prostate‐specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross‐sectional study
  BJU International, 2004
• Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate
  New England Journal of Medicine, 1987